Organon & Co.

Organon & Co. is a global healthcare company that focuses primarily on the discovery, development, manufacture, and commercialization of therapeutic solutions. Its primary function is to address the needs of women, with a significant emphasis on family planning and fertility products. Organon operates in important healthcare sectors, notably women’s health, biosimilars, and established brands across various therapeutic areas. The company’s product portfolio includes contraceptive products, fertility treatments, and a range of hormone replacement therapies. Organon was spun off from Merck & Co. in 2021, marking its emergence as a standalone entity aimed at focusing more intensively on women’s health issues. This strategic shift allows Organon to leverage its expertise in pharmaceutical development and expand its reach in global markets, particularly in areas underserved by larger healthcare conglomerates. Situated in the healthcare sector, Organon plays a crucial role by continuing to provide specialized pharmaceuticals designed to meet unique health needs, thereby contributing significantly to public health and therapy innovations.